echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Johnson and Johnson reached a $1 billion new crown vaccine supply agreement with the U.S. government, priced at $10 per dose.

    Johnson and Johnson reached a $1 billion new crown vaccine supply agreement with the U.S. government, priced at $10 per dose.

    • Last Update: 2020-09-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    With the development of many new crown vaccines coming to the late stages of clinical trials, countries around the world are racing to implement vaccine production and supply for mass immunization programs.
    U.S. government has struck a deal worth more than $1 billion with Johnson and Johnson to secure 100 million doses of the company's experimental new coronavirus vaccine, the Financial Times reported On Monday.
    announced on July 16th that the final phase of clinical trials of the new crown vaccine under development would be advanced as soon as September, when it was expected to be in the first half of 2021.
    is understood that Johnson and Johnson's new crown vaccine clinical trial study includes phase 1/2a and phase 3 clinical plans, in which both Ad26.COV2.S single-dose and dual-dose options will be evaluated.
    currently, the first human clinical studies in Phase 1/2a are being conducted in the United States and Belgium.
    the trial will evaluate the safety, responsiveness (response to vaccination, such as swelling or soreness) and immunogenicity of the Ad26.COV2.S vaccine.
    , Johnson and Johnson will conduct Phase 2 studies in the Netherlands, Spain and Germany, and plans to conduct Phase 1/2a studies in Japan.
    September, Johnson and Johnson will conduct Phase 3 clinical trials comparing single-dose vaccines to placebos.
    same period, a phase 3 clinical trial of a two-dose vaccine compared to a placebo will be conducted.
    prices of vaccines have been revealed, Moderna is seeking to return vaccine research and development has not yet reached the end, countries have begun to "crazy" to sign cooperation agreements, which also allowed the price of vaccines to be spied on by the outside world.
    the agreement was announced, Moderna, the biotech company that developed the new mRNA vaccine, announced its pricing.
    said it had offered prices for some "small-volume" buyers, charging between $32 and $37 per dose of mRNA-1273.
    price is almost double the price of Pfizer's vaccine partnership with BioNTech.
    From recent deals, GSK and Sanofi's new crown vaccine costs $21 per dose; Pfizer and BioNTech's new crown vaccine costs $19.50 per dose; AstraZeneta and Oxford University's vaccine cost about $3 to $4 per dose; and Johnson and Johnson's supply agreement with the U.S. government means about $10 per dose.
    's mRNA vaccine has been a front-runner in the development of the new crown vaccine and is seen as the first gold medalist to break through.
    , the long-lost Modelna has received nearly $1 billion in U.S. government funding.
    phase III randomized double-blind controlled clinical trial was launched July 27 in 87 districts across the United States, recruiting 30,000 volunteers.
    , according to media reports, Moderna has said it expects to deliver about 500 million doses a year starting in 2021, up to a maximum of 1 billion doses.
    but unlike Johnson and Johnson and AstraZeneta, which said they would not profit from the new crown vaccine in the first place, Moderna and Pfizer and BioNTech said they would seek some return.
    financial times reported last week that Moderna was selling its new crown vaccine to potential buyers for about $50 to $60 per course of treatment.
    now, Moderna has left room for manoeuvre after revealing that vaccines cost between $32 and $37 per dose.
    Moderna said on Wednesday that negotiations were under way to bring lower prices per dose on a larger deal.
    , Moderna's chief executive, told analysts: "During the pandemic, our pricing was well below value, mainly because of the government's pre-approval of supply agreements.
    " but he also said, "In times of pandemic, pricing considerations will follow traditional factors and market forces, including vaccine effectiveness and competitive landscape, and we will seek to maintain the same price level as other innovative commercial vaccines."
    " According to file pharma, Moderna's new crown vaccine is not expected to reach phase 3 preliminary results until at least October, but Moderna has been in discussions with several countries to sell a dose of the vaccine to several countries if successful.
    that by the end of July, Moderna had received a deposit of about $400 million.
    , which is not yet available on the market, narrowed its second-quarter loss to $117 million from $135 million in the same period in 2019, led by the new crown vaccine.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.